Virus Testing Diagnostic Kits market is anticipated to reach US$26.24 Billion in 2026: Visiongain Research Inc


Visiongain has published a new report on “Virus Testing Diagnostic Kits Market Report 2021-2031”. Forecasts by Test Type (DFA Tests, Lateral Flow Tests, RT-PCR, Agglutination Assays, Solid-Phase Assays, Others), Application (Influenza, Hepatitis, HIV, Measles/Rubella, Rotavirus, Others); End-User (Laboratories, Hospitals, Home-Care Settings, Academic Institutes), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), PLUS COVID-19 Recovery Scenarios.

This report evaluates the virus testing diagnostic kits market for the period, 2021-2031. ‘The global virus testing diagnostic kits market is estimated to be valued at US$19.9 billion in 2020 and is anticipated to reach US$26.24 billion in 2026. The global market size is further projected to reach US$34.29 billion by 2031’ says Visiongain’s lead analyst.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/virus-testing-kits-market-2021/#download_sampe_div

COVID-19 Impact on Virus Diagnostic Kits Market
At the global level, the COVID-19 epidemic has created an ongoing public health crisis. In the stage of deconfinement and social changes and beyond, diagnostic testing will remain a core pillar. The diagnostic industry is committed to contributing and collaborating with policymakers and other stakeholders to play its part in ensuring that the lives and health of people can be secured as the world continues to tackle the pandemic.

Growing Disease Burden
With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper diagnosis as well as full proof treatment positions for various chronic diseases. With increasing awareness regarding symptoms of various terminal illnesses, the diagnosis rates have been improving in developing countries such as China, India, Japan, Brazil, and other southeast Asian countries. Despite the availability of technologically advanced equipment for diagnosis, a small amount of human error has been breaking the process. With this error, a noticeable amount of the patients remains undiagnosed at an early stage making the treatment complicated.

Growing Burden of Influenza to Fuel Demand for Virus Diagnostic Kits Market
Epidemics and pandemics of influenza have an enormous effect on the population and individuals. The weight and extent of the influenza burden vary with the patient's age and underlying health. The disease places a major burden on all people, but in high-risk patients (the elderly and those with some underlying medical conditions) hospitalization and care occur more often; patient populations are rising in size. The need to measure the burden of influenza has been intensified by escalating medical costs. In all such studies, the first step is to assess the prevalence of the disease; this is frequently under-reported for influenza, as the disease can be confused with other viral diseases. In addition to the direct costs of medical care, which derive mainly from absenteeism & loss of work efficiency, the indirect costs of influenza are high. Cost estimates for influenza have shown that in France, the United States, and Germany that indirect costs can be five to 10 times higher than direct costs.

Get Detailed TOC @ https://www.visiongain.com/report/virus-testing-kits-market-2021/#download_sampe_div

Other intangible influenza-related costs include reduced efficiency, which can improve response times, and adverse effects on patients' and their families' quality of life. In this sense, therefore the costs of interventions should be considered. The administration of vaccines is the primary solution to influenza prevention and its related costs. Although vaccinations are broadly successful, the greatest possible benefits are shown in high-risk populations, so vaccination is recommended for high-risk patients, their caregivers, and healthcare workers in several countries.

Competitive Landscape
Some of the companies profiled in the report include Quidel Corporation, F. Hoffmann-La Roche, Alere Inc., Abbott, Thermo Fisher Scientific, Becton, Dickinson and Company, Luminex Corporation, Beckman Coulter, Inc., Cortez Diagnostics, and Bundi International Diagnostics.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Virus testing diagnostic kits market and leading companies. You will find data, trends and predictions.

Find more Visiongain research reports on Pharma Diagnostics Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.